Rhenovia Pharma

Rhenovia launches rare, orphan and neglected disease drug discovery

Monday, March 19, 2012 12:22 PM

Rhenovia Pharma, a biosimulation biotech company based in Mulhouse, France and Cambridge, Mass., has initiated drug research programs in rare, orphan and neglected neurodegenerative diseases.

More... »


Rhenovia Pharma opens first U.S. office

Wednesday, January 25, 2012 01:55 PM

Rhenovia Pharma, a biotechnology company specializing in biosimulation to aid discovery of treatments for brain diseases, has formed its first international subsidiary, Rhenovia Inc. The new operation will be based in Cambridge, Mass.

More... »


Rhenovia’s RHETOX project receives EUR 1.15 million in financing

Thursday, September 1, 2011 11:06 AM

Rhenovia Pharma has been selected by the French Armaments Directorate (DGA) and the General Directorate for Competitiveness, Industry and Services of the French Ministry of Economy, Finance and Industry (DGCIS) for inclusion in the RAPID program (Support Regime for Dual Innovation in SMEs). By this distinction, Rhenovia will lead a research program, named RHETOX, which will be conducted in partnership with the French Army’s Biomedical Research Institute (IRBA). Rhenovia will receive EUR 850,000 from a global funding amount of EUR 1.15 million.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.